Nevertheless, miR-34a remains a compelling therapeutic target, as its reactivation can simultaneously drive cancer cells into apoptosis and reduce immune-evasion signals (e.g., PD-L1 and other immune escape genes) that foster tumor survival. This evidence concerns the gene CD274 and cancer.